# Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer

> **NCT03841747** · PHASE2 · WITHDRAWN · sponsor: **Queen Mary University of London**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03841747
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12
- **Primary completion:** 2023-06
- **Final completion:** 2025-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding restrictions
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03841747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03841747, "Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03841747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*